{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:12:48Z","timestamp":1788469968459,"version":"build-2803163510"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04307-1","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:50:17Z","timestamp":1776786617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unraveling the multidimensional pleural ecosystem of lung cancer-associated malignant pleural effusion"],"prefix":"10.1186","volume":"26","author":[{"given":"Shuting","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"11","key":"4307_CR1","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/thorax-2023-220304","volume":"78","author":"ME Roberts","year":"2023","unstructured":"Roberts ME, et al. British Thoracic Society Guideline for pleural disease. Thorax. 2023;78(11):1143\u201356.","journal-title":"Thorax"},{"issue":"3","key":"4307_CR2","first-page":"114","volume":"53","author":"S Park","year":"2020","unstructured":"Park S, et al. The Role of Primary Tumor Resection in Patients with Pleural Metastasis Encountered at the Time of Surgery. J Chest Surg. 2020;53(3):114\u201320.","journal-title":"J Chest Surg"},{"issue":"10","key":"4307_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/JTO.0b013e318267223a","volume":"7","author":"D Morgensztern","year":"2012","unstructured":"Morgensztern D, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):1485\u20139.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4307_CR4","doi-asserted-by":"publisher","first-page":"e1554969","DOI":"10.1080\/2162402X.2018.1554969","volume":"8","author":"P Murthy","year":"2019","unstructured":"Murthy P, et al. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8(4):e1554969.","journal-title":"Oncoimmunology"},{"key":"4307_CR5","doi-asserted-by":"publisher","first-page":"106802","DOI":"10.1016\/j.rmed.2022.106802","volume":"196","author":"SI Bashour","year":"2022","unstructured":"Bashour SI, Mankidy BJ, Lazarus DR. Update on the diagnosis and management of malignant pleural effusions. Respir Med. 2022;196:106802.","journal-title":"Respir Med"},{"issue":"8","key":"4307_CR6","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.21037\/jtd-2025-113","volume":"17","author":"R Westley","year":"2025","unstructured":"Westley R, De Fonseka D, Bedawi EO. Updates in the management of malignant pleural effusion: a clinical practice review. J Thorac Dis. 2025;17(8):6283\u201395.","journal-title":"J Thorac Dis"},{"issue":"2","key":"4307_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s44321-025-00363-8","volume":"18","author":"AT Woods","year":"2026","unstructured":"Woods AT, et al. Pathobiology and clinical significance of malignant pleural effusions. EMBO Mol Med. 2026;18(2):396\u2013432.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"4307_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1200\/OP-24-00925","volume":"21","author":"V Duong","year":"2025","unstructured":"Duong V, Hargreaves B, Muruganandan S. Management of Malignant Pleural Effusion in 2024: A Definitive and Unified Global Approach. JCO Oncol Pract. 2025;21(6):739\u201341.","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"4307_CR9","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.21037\/jtd-2024-1999","volume":"17","author":"J Wang","year":"2025","unstructured":"Wang J, et al. Malignant pleural effusion is a negative prognostic factor for immunotherapy outcomes in non-small cell lung cancer: a single-center retrospective study. J Thorac Dis. 2025;17(5):3064\u201372.","journal-title":"J Thorac Dis"},{"issue":"4","key":"4307_CR10","doi-asserted-by":"publisher","first-page":"230145","DOI":"10.1183\/20734735.0145-2023","volume":"19","author":"LM Piggott","year":"2024","unstructured":"Piggott LM, et al. Malignant pleural disease. Breathe. 2024;19(4):230145.","journal-title":"Breathe"},{"issue":"1","key":"4307_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","volume":"7","author":"AD Donnenberg","year":"2019","unstructured":"Donnenberg AD, et al. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019;7(1):110.","journal-title":"J Immunother Cancer"},{"issue":"21","key":"4307_CR12","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"4307_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/17476348.2018.1417042","volume":"12","author":"RL Sabang","year":"2018","unstructured":"Sabang RL, et al. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med. 2018;12(2):87\u201394.","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"4307_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer. Immunity. 2019;50(4):924\u201340.","journal-title":"Immunity"},{"issue":"1","key":"4307_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jmedgenet-2018-105439","volume":"56","author":"X Wang","year":"2019","unstructured":"Wang X, et al. Exosomes derived from exhausted CD8\u2009+\u2009T cells impaired the anticancer function of normal CD8\u2009+\u2009T cells. J Med Genet. 2019;56(1):29\u201331.","journal-title":"J Med Genet"},{"issue":"6","key":"4307_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-017-1979-x","volume":"66","author":"H Prado-Garcia","year":"2017","unstructured":"Prado-Garcia H, et al. The PD-L1\/PD-1 pathway promotes dysfunction, but not exhaustion, in tumor-responding T cells from pleural effusions in lung cancer patients. Cancer Immunol Immunother. 2017;66(6):765\u201376.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4307_CR17","doi-asserted-by":"publisher","first-page":"113212","DOI":"10.1016\/j.yexcr.2022.113212","volume":"417","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Phenotypic and functional characterizations of CD8(+) T cell populations in malignant pleural effusion. Exp Cell Res. 2022;417(1):113212.","journal-title":"Exp Cell Res"},{"issue":"7","key":"4307_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00262-011-1165-5","volume":"61","author":"H Prado-Garcia","year":"2012","unstructured":"Prado-Garcia H, et al. Activation-induced cell death of memory CD8\u2009+\u2009T cells from pleural effusion of lung cancer patients is mediated by the type II Fas-induced apoptotic pathway. Cancer Immunol Immunother. 2012;61(7):1065\u201380.","journal-title":"Cancer Immunol Immunother"},{"key":"4307_CR19","doi-asserted-by":"crossref","unstructured":"Tilsed CM, Brotman J, O'Brien S, Lee B, Moon E, Albelda SM. Identification and characterization of tissue resident memory T cells in malignant pleural effusions associated with non-small cell lung cancer. Immunohorizons. 2025 Apr 26;9(6):vlaf013.","DOI":"10.1093\/immhor\/vlaf013"},{"issue":"1","key":"4307_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12865-023-00590-z","volume":"24","author":"LL Lv","year":"2023","unstructured":"Lv LL, et al. CD39 identifies a specific CD8\u2009+\u2009T cell population in lung adenocarcinoma-related metastatic pleural effusion. BMC Immunol. 2023;24(1):53.","journal-title":"BMC Immunol"},{"issue":"1","key":"4307_CR21","doi-asserted-by":"publisher","first-page":"2371556","DOI":"10.1080\/2162402X.2024.2371556","volume":"13","author":"Y Sugita","year":"2024","unstructured":"Sugita Y, et al. Candidate tumor-specific CD8(+) T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis. Oncoimmunology. 2024;13(1):2371556.","journal-title":"Oncoimmunology"},{"key":"4307_CR22","doi-asserted-by":"crossref","unstructured":"Komuro H et al. Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer\/testis antigen in non-small cell lung cancer. J Immunother Cancer. 2023 Aug;11(8):e007180.","DOI":"10.1136\/jitc-2023-007180"},{"issue":"2","key":"4307_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. Immunity. 2019;50(2):302\u201316.","journal-title":"Immunity"},{"key":"4307_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi S, et al. Regulatory T Cells and Human Disease. Annu Rev Immunol. 2020;38:541\u201366.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"4307_CR25","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1164\/rccm.200504-588OC","volume":"172","author":"YQ Chen","year":"2005","unstructured":"Chen YQ, et al. CD4\u2009+\u2009CD25+ regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med. 2005;172(11):1434\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"4307_CR26","doi-asserted-by":"publisher","first-page":"107847","DOI":"10.1016\/j.lungcan.2024.107847","volume":"193","author":"K Mahmood","year":"2024","unstructured":"Mahmood K, et al. Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing. Lung Cancer. 2024;193:107847.","journal-title":"Lung Cancer"},{"issue":"1","key":"4307_CR27","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.1038\/s41467-021-27026-9","volume":"12","author":"ZY Huang","year":"2021","unstructured":"Huang ZY, et al. Single-cell analysis of diverse immune phenotypes in malignant pleural effusion. Nat Commun. 2021;12(1):6690.","journal-title":"Nat Commun"},{"issue":"24","key":"4307_CR28","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.21037\/atm-20-7181","volume":"8","author":"LL Ye","year":"2020","unstructured":"Ye LL, et al. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. Ann Transl Med. 2020;8(24):1647.","journal-title":"Ann Transl Med"},{"issue":"12","key":"4307_CR29","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1158\/1535-7163.MCT-14-0448","volume":"13","author":"M Lv","year":"2014","unstructured":"Lv M, et al. miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer. Mol Cancer Ther. 2014;13(12):3152\u201362.","journal-title":"Mol Cancer Ther"},{"key":"4307_CR30","doi-asserted-by":"crossref","unstructured":"Xue Q et al. Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion. J Immunother Cancer. 2024 Dec 25;12(12):e010040.","DOI":"10.1136\/jitc-2024-010040"},{"issue":"11","key":"4307_CR31","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1038\/s12276-025-01557-3","volume":"57","author":"L Ye","year":"2025","unstructured":"Ye L, et al. H3K18 lactylation in cancer-associated fibroblasts drives malignant pleural effusion progression via TNFR2(+) T(reg) recruitment. Exp Mol Med. 2025;57(11):2671\u201385.","journal-title":"Exp Mol Med"},{"issue":"10","key":"4307_CR32","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.1001728","volume":"185","author":"ZJ Ye","year":"2010","unstructured":"Ye ZJ, et al. Generation and differentiation of IL-17-producing CD4\u2009+\u2009T cells in malignant pleural effusion. J Immunol. 2010;185(10):6348\u201354.","journal-title":"J Immunol"},{"issue":"1","key":"4307_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2012.07.013","volume":"326","author":"ZJ Ye","year":"2012","unstructured":"Ye ZJ, et al. Interleukin 22-producing CD4\u2009+\u2009T cells in malignant pleural effusion. Cancer Lett. 2012;326(1):23\u201332.","journal-title":"Cancer Lett"},{"issue":"20","key":"4307_CR34","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-07-4401","volume":"14","author":"W Zhang","year":"2008","unstructured":"Zhang W, et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res. 2008;14(20):6432\u20139.","journal-title":"Clin Cancer Res"},{"issue":"31","key":"4307_CR35","doi-asserted-by":"publisher","first-page":"12885","DOI":"10.1073\/pnas.0812530106","volume":"106","author":"W Elyaman","year":"2009","unstructured":"Elyaman W, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3\u2009+\u2009natural regulatory T cells. Proc Natl Acad Sci U S A. 2009;106(31):12885\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"4307_CR36","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.201207-1307OC","volume":"186","author":"ZJ Ye","year":"2012","unstructured":"Ye ZJ, et al. Differentiation and immune regulation of IL-9-producing CD4\u2009+\u2009T cells in malignant pleural effusion. Am J Respir Crit Care Med. 2012;186(11):1168\u201379.","journal-title":"Am J Respir Crit Care Med"},{"key":"4307_CR37","doi-asserted-by":"publisher","first-page":"105766","DOI":"10.1016\/j.intimp.2019.105766","volume":"75","author":"J He","year":"2019","unstructured":"He J, et al. Interleukin-9 promotes tumorigenesis through augmenting angiogenesis in non-small cell lung cancer. Int Immunopharmacol. 2019;75:105766.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"4307_CR38","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s11427-016-0097-y","volume":"59","author":"Y Lu","year":"2016","unstructured":"Lu Y, et al. Interleukin-17 inhibits development of malignant pleural effusion via interleukin-9-dependent mechanism. Sci China Life Sci. 2016;59(12):1297\u2013304.","journal-title":"Sci China Life Sci"},{"issue":"6","key":"4307_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1164\/rccm.201310-1776OC","volume":"189","author":"H Lin","year":"2014","unstructured":"Lin H, et al. Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion. Am J Respir Crit Care Med. 2014;189(6):697\u2013706.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4307_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1465-9921-12-77","volume":"12","author":"ZJ Ye","year":"2011","unstructured":"Ye ZJ, et al. CD39\u2009+\u2009regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res. 2011;12(1):77.","journal-title":"Respir Res"},{"issue":"4","key":"4307_CR41","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/eji.201847685","volume":"49","author":"XZ Wu","year":"2019","unstructured":"Wu XZ, et al. IL-10 promotes malignant pleural effusion in mice by regulating T(H) 1- and T(H) 17-cell differentiation and migration. Eur J Immunol. 2019;49(4):653\u201365.","journal-title":"Eur J Immunol"},{"issue":"1","key":"4307_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/JLB.1MA0221-479RR","volume":"110","author":"Y Niu","year":"2021","unstructured":"Niu Y, et al. IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4(+) IL-22(+) T-cell differentiation and inhibiting CD8(+) T-cell cytotoxicity. J Leukoc Biol. 2021;110(1):39\u201352.","journal-title":"J Leukoc Biol"},{"key":"4307_CR43","doi-asserted-by":"crossref","unstructured":"Liang Y et al. Increase CD24\u2009+\u2009CD27+ B cells within pleural effusions derived from lung adenocarcinoma presents enhanced potential for clinical utility. Immunobiology. 2025:153109.","DOI":"10.1016\/j.imbio.2025.153109"},{"key":"4307_CR44","doi-asserted-by":"publisher","first-page":"626776","DOI":"10.3389\/fimmu.2021.626776","volume":"12","author":"C Germain","year":"2021","unstructured":"Germain C, et al. Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. Front Immunol. 2021;12:626776.","journal-title":"Front Immunol"},{"issue":"3","key":"4307_CR45","doi-asserted-by":"publisher","first-page":"L443","DOI":"10.1152\/ajplung.00120.2018","volume":"315","author":"X-Z Wu","year":"2018","unstructured":"Wu X-Z, et al. Activated na\u00efve B cells promote development of malignant pleural effusion by differential regulation of TH1 and TH17 response. Am J Physiology-Lung Cell Mol Physiol. 2018;315(3):L443\u201355.","journal-title":"Am J Physiology-Lung Cell Mol Physiol"},{"issue":"3","key":"4307_CR46","doi-asserted-by":"publisher","first-page":"L443","DOI":"10.1152\/ajplung.00120.2018","volume":"315","author":"XZ Wu","year":"2018","unstructured":"Wu XZ, et al. Activated na\u00efve B cells promote development of malignant pleural effusion by differential regulation of T(H)1 and T(H)17 response. Am J Physiol Lung Cell Mol Physiol. 2018;315(3):L443\u201355.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"4307_CR47","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1186\/s12885-017-3615-8","volume":"17","author":"C Chen","year":"2017","unstructured":"Chen C, et al. Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists. BMC Cancer. 2017;17(1):652.","journal-title":"BMC Cancer"},{"key":"4307_CR48","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, et al. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020;11:583084.","journal-title":"Front Immunol"},{"key":"4307_CR49","doi-asserted-by":"crossref","unstructured":"Boutilier AJ, Elsawa SF. Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021 Jun 29;22(13):6995.","DOI":"10.3390\/ijms22136995"},{"key":"4307_CR50","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.intimp.2022.109235","volume":"112","author":"X Xiong","year":"2022","unstructured":"Xiong X, et al. Tumor-associated macrophages in lymphoma: From mechanisms to therapy. Int Immunopharmacol. 2022;112:109235.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"4307_CR51","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.18632\/oncotarget.3547","volume":"6","author":"L Yang","year":"2015","unstructured":"Yang L, et al. CD163\u2009+\u2009tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. Oncotarget. 2015;6(12):10592\u2013603.","journal-title":"Oncotarget"},{"key":"4307_CR52","doi-asserted-by":"crossref","unstructured":"Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases. Int J Mol Sci. 2020 Jul 31;21(15):5497.","DOI":"10.3390\/ijms21155497"},{"issue":"2","key":"4307_CR53","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1161\/CIRCRESAHA.123.324082","volume":"135","author":"M Mori","year":"2024","unstructured":"Mori M, et al. CD163(+) Macrophages Induce Endothelial-to-Mesenchymal Transition in Atheroma. Circ Res. 2024;135(2):e4\u201323.","journal-title":"Circ Res"},{"key":"4307_CR54","doi-asserted-by":"publisher","first-page":"106970","DOI":"10.1016\/j.imlet.2025.106970","volume":"272","author":"H Mathiesen","year":"2025","unstructured":"Mathiesen H, et al. Prognostic value of CD163(+) macrophages in solid tumor malignancies: A scoping review. Immunol Lett. 2025;272:106970.","journal-title":"Immunol Lett"},{"key":"4307_CR55","doi-asserted-by":"crossref","unstructured":"Zhang S et al. C1q+ tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. J Immunother Cancer. 2023 Aug;11(8):e007441.","DOI":"10.1136\/jitc-2023-007441"},{"issue":"13","key":"4307_CR56","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.7150\/thno.85084","volume":"13","author":"YY Wu","year":"2023","unstructured":"Wu YY, et al. Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer. Theranostics. 2023;13(13):4412\u201329.","journal-title":"Theranostics"},{"issue":"4","key":"4307_CR57","doi-asserted-by":"publisher","first-page":"e23638","DOI":"10.4161\/onci.23638","volume":"2","author":"P Vacca","year":"2013","unstructured":"Vacca P, et al. NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy? Oncoimmunology. 2013;2(4):e23638.","journal-title":"Oncoimmunology"},{"issue":"4","key":"4307_CR58","doi-asserted-by":"publisher","first-page":"e1293210","DOI":"10.1080\/2162402X.2017.1293210","volume":"6","author":"D Croxatto","year":"2017","unstructured":"Croxatto D, et al. IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid. Oncoimmunology. 2017;6(4):e1293210.","journal-title":"Oncoimmunology"},{"key":"4307_CR59","doi-asserted-by":"publisher","first-page":"p2438598","DOI":"10.1155\/2018\/2438598","volume":"2018","author":"A Bosi","year":"2018","unstructured":"Bosi A, et al. Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization. J Immunol Res. 2018;2018:p2438598.","journal-title":"J Immunol Res"},{"issue":"5","key":"4307_CR60","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00262-020-02510-1","volume":"69","author":"FF Gu","year":"2020","unstructured":"Gu FF, et al. Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation. Cancer Immunol Immunother. 2020;69(5):779\u201388.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"4307_CR61","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.7150\/ijbs.116499","volume":"21","author":"YM Tsai","year":"2025","unstructured":"Tsai YM, et al. Senescent Tumoral HLA-E Reshapes Microenvironment through Impairing NK Cell-Dendritic Cell-T Cell Network in Malignant Pleural Effusion from Lung Cancer. Int J Biol Sci. 2025;21(12):5240\u201357.","journal-title":"Int J Biol Sci"},{"issue":"15","key":"4307_CR62","doi-asserted-by":"publisher","first-page":"e2103222","DOI":"10.1002\/advs.202103222","volume":"9","author":"JJ Lai","year":"2022","unstructured":"Lai JJ, et al. Exosome Processing and Characterization Approaches for Research and Technology Development. Adv Sci (Weinh). 2022;9(15):e2103222.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"4307_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gpb.2015.02.001","volume":"13","author":"J Zhang","year":"2015","unstructured":"Zhang J, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteom Bioinf. 2015;13(1):17\u201324.","journal-title":"Genomics Proteom Bioinf"},{"issue":"13Supplement","key":"4307_CR64","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1158\/1538-7445.AM2017-1815","volume":"77","author":"C-C Lin","year":"2017","unstructured":"Lin C-C, Huang W-L, Su W-C. Extracellular vesicles derived from lung cancer cell may contribute to the formation of malignant pleural effusion via activating Stat3\/Tissue factor\/VEGF. Cancer Res. 2017;77(13Supplement):1815\u20131815.","journal-title":"Cancer Res"},{"key":"4307_CR65","doi-asserted-by":"publisher","first-page":"101564","DOI":"10.1016\/j.tranon.2022.101564","volume":"27","author":"J Wu","year":"2023","unstructured":"Wu J, et al. Exosomes in malignant pleural effusion from lung cancer patients impaired the cytotoxicity of double-negative T cells. Translational Oncol. 2023;27:101564.","journal-title":"Translational Oncol"},{"issue":"2","key":"4307_CR66","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"4307_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s13577-025-01322-8","volume":"39","author":"G Cammarata","year":"2025","unstructured":"Cammarata G, et al. Effects of small extracellular vesicles isolated from pleural effusion on lung cancer cell proliferation and migration. Hum Cell. 2025;39(1):10.","journal-title":"Hum Cell"},{"issue":"8","key":"4307_CR68","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1002\/cam4.2928","volume":"9","author":"S Watabe","year":"2020","unstructured":"Watabe S, et al. Clinicopathological significance of microRNA-21 in extracellular vesicles of pleural lavage fluid of lung adenocarcinoma and its functions inducing the mesothelial to mesenchymal transition. Cancer Med. 2020;9(8):2879\u201390.","journal-title":"Cancer Med"},{"issue":"1","key":"4307_CR69","doi-asserted-by":"publisher","first-page":"124","DOI":"10.21037\/tlcr-24-945","volume":"14","author":"TM Chee","year":"2025","unstructured":"Chee TM, et al. Potential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions. Transl Lung Cancer Res. 2025;14(1):124\u201338.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"4307_CR70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-015-0421-2","volume":"14","author":"A Alsuliman","year":"2015","unstructured":"Alsuliman A, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. Mol Cancer. 2015;14(1):149.","journal-title":"Mol Cancer"},{"key":"4307_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.humpath.2016.07.007","volume":"58","author":"S Kim","year":"2016","unstructured":"Kim S, et al. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol. 2016;58:7\u201314.","journal-title":"Hum Pathol"},{"key":"4307_CR72","doi-asserted-by":"crossref","unstructured":"Soler MF et al. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer. 2023 Nov;11(11):e007530.","DOI":"10.1136\/jitc-2023-007530"},{"issue":"4","key":"4307_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Reviews Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"3","key":"4307_CR74","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.","journal-title":"J Exp Med"},{"issue":"5","key":"4307_CR75","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.neo.2019.03.009","volume":"21","author":"J Hao","year":"2019","unstructured":"Hao J, et al. Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion. Neoplasia. 2019;21(5):482\u201393.","journal-title":"Neoplasia"},{"issue":"1","key":"4307_CR76","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12931-025-03263-0","volume":"26","author":"Q Cheng","year":"2025","unstructured":"Cheng Q, et al. Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion. Respir Res. 2025;26(1):180.","journal-title":"Respir Res"},{"issue":"3","key":"4307_CR77","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396\u2013e4125.","journal-title":"Cancer Cell"},{"key":"4307_CR78","doi-asserted-by":"crossref","unstructured":"Razavi MS, Munn LL, Padera TP. Mechanics of Lymphatic Pumping and Lymphatic Function. Volume 15. Cold Spring Harb Perspect Med; 2025. 3.","DOI":"10.1101\/cshperspect.a041171"},{"issue":"1","key":"4307_CR79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","volume":"25","author":"F Gonnelli","year":"2024","unstructured":"Gonnelli F, Hassan W, Bonifazi M, Pinelli V, Bedawi EO, Porcel JM, Rahman NM, Mei F. Malignant pleural effusion: current understanding and therapeutic approach. Respir Res. 2024 Jan 19;25(1):47.","journal-title":"Respir Res"},{"issue":"6","key":"4307_CR80","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0002-9440(10)64828-6","volume":"157","author":"S Yano","year":"2000","unstructured":"Yano S, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor\/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157(6):1893\u2013903.","journal-title":"Am J Pathol"},{"issue":"1","key":"4307_CR81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s43088-023-00366-9","volume":"12","author":"MM El-Kalashy","year":"2023","unstructured":"El-Kalashy MM, et al. Role of GSDMD and VEGF in differentiating between malignant and non-malignant pleural effusions. Beni-Suef Univ J Basic Appl Sci. 2023;12(1):28.","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"issue":"1","key":"4307_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2013.07.007","volume":"82","author":"EA Lieser","year":"2013","unstructured":"Lieser EA, et al. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions. Lung Cancer. 2013;82(1):63\u20138.","journal-title":"Lung Cancer"},{"issue":"3","key":"4307_CR83","first-page":"381","volume":"13","author":"WB Zhou","year":"2009","unstructured":"Zhou WB, Bai M, Jin Y. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis. 2009;13(3):381\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"4307_CR84","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1080\/02841860701280733","volume":"46","author":"J Shu","year":"2007","unstructured":"Shu J, et al. Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions. Acta Oncol. 2007;46(7):1004\u201311.","journal-title":"Acta Oncol"},{"issue":"6","key":"4307_CR85","first-page":"8019","volume":"17","author":"Y Chen","year":"2018","unstructured":"Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non\u2013small cell lung cancer (Review). Mol Med Rep. 2018;17(6):8019\u201330.","journal-title":"Mol Med Rep"},{"issue":"19","key":"4307_CR86","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.7314\/APJCP.2014.15.19.8435","volume":"15","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, et al. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer. Asian Pac J Cancer Prev. 2014;15(19):8435\u201340.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"4307_CR87","doi-asserted-by":"publisher","first-page":"e1649","DOI":"10.1002\/ctm2.1649","volume":"14","author":"X Zhang","year":"2024","unstructured":"Zhang X, et al. Single-cell transcriptomics reveal metastatic CLDN4\u2009+\u2009cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer. Clin Transl Med. 2024;14(4):e1649.","journal-title":"Clin Transl Med"},{"issue":"3","key":"4307_CR88","first-page":"957","volume":"6","author":"S Yano","year":"2000","unstructured":"Yano S, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6(3):957\u201365.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4307_CR89","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.2217\/fon-2018-0089","volume":"14","author":"D Chen","year":"2018","unstructured":"Chen D, et al. Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more. Future Oncol. 2018;14(21):2131\u20138.","journal-title":"Future Oncol"},{"issue":"11","key":"4307_CR90","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/ni.3836","volume":"18","author":"A Johansson-Percival","year":"2017","unstructured":"Johansson-Percival A, et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol. 2017;18(11):1207\u201317.","journal-title":"Nat Immunol"},{"issue":"3","key":"4307_CR91","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","volume":"125","author":"AL Magnussen","year":"2021","unstructured":"Magnussen AL, Mills IG. Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br J Cancer. 2021;125(3):324\u201336.","journal-title":"Br J Cancer"},{"issue":"5","key":"4307_CR92","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/thx.37.5.354","volume":"37","author":"T Pettersson","year":"1982","unstructured":"Pettersson T, Klockars M, Hellstr\u00f6m PE. Chemical and immunological features of pleural effusions: comparison between rheumatoid arthritis and other diseases. Thorax. 1982;37(5):354\u201361.","journal-title":"Thorax"},{"issue":"6","key":"4307_CR93","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1183\/09031936.00015710","volume":"37","author":"CC Lin","year":"2011","unstructured":"Lin CC, et al. Malignant pleural effusion cells show aberrant glucose metabolism gene expression. Eur Respir J. 2011;37(6):1453\u201365.","journal-title":"Eur Respir J"},{"issue":"762","key":"4307_CR94","doi-asserted-by":"publisher","first-page":"eadk7399","DOI":"10.1126\/scitranslmed.adk7399","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Activation and antitumor immunity of CD8(+) T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid. Sci Transl Med. 2024;16(762):eadk7399.","journal-title":"Sci Transl Med"},{"issue":"7519","key":"4307_CR95","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559\u201363.","journal-title":"Nature"},{"issue":"1","key":"4307_CR96","doi-asserted-by":"publisher","first-page":"113962","DOI":"10.1016\/j.yexcr.2024.113962","volume":"436","author":"L Liu","year":"2024","unstructured":"Liu L, et al. Acidity-induced ITGB6 promote migration and invasion of lung cancer cells by epithelial-mesenchymal transition and focal adhesion. Exp Cell Res. 2024;436(1):113962.","journal-title":"Exp Cell Res"},{"issue":"4","key":"4307_CR97","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.apsb.2022.10.027","volume":"13","author":"M Zheng","year":"2023","unstructured":"Zheng M, et al. The impact of lipids on the cancer\u2013immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy. Acta Pharm Sinica B. 2023;13(4):1488\u201397.","journal-title":"Acta Pharm Sinica B"},{"issue":"9","key":"4307_CR98","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1021\/pr5003774","volume":"13","author":"CW Lam","year":"2014","unstructured":"Lam CW, Law CY. Untargeted mass spectrometry-based metabolomic profiling of pleural effusions: fatty acids as novel cancer biomarkers for malignant pleural effusions. J Proteome Res. 2014;13(9):4040\u20136.","journal-title":"J Proteome Res"},{"key":"4307_CR99","doi-asserted-by":"publisher","first-page":"1307228","DOI":"10.3389\/fimmu.2023.1307228","volume":"14","author":"Y Long","year":"2023","unstructured":"Long Y, et al. Analyzing the impact of metabolism on immune cells in tumor microenvironment to promote the development of immunotherapy. Front Immunol. 2023;14:1307228.","journal-title":"Front Immunol"},{"issue":"4","key":"4307_CR100","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4307_CR101","doi-asserted-by":"publisher","first-page":"116512","DOI":"10.1016\/j.biopha.2024.116512","volume":"174","author":"W Zhang","year":"2024","unstructured":"Zhang W, et al. GPX4, ferroptosis, and diseases. Biomed Pharmacother. 2024;174:116512.","journal-title":"Biomed Pharmacother"},{"issue":"Pt 2","key":"4307_CR102","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.freeradbiomed.2022.11.018","volume":"193","author":"N Zhang","year":"2022","unstructured":"Zhang N, et al. Ferritin confers protection against iron-mediated neurotoxicity and ferroptosis through iron chelating mechanisms in MPP(+)-induced MES23.5 dopaminergic cells. Free Radic Biol Med. 2022;193(Pt 2):751\u201363.","journal-title":"Free Radic Biol Med"},{"key":"4307_CR103","doi-asserted-by":"crossref","unstructured":"Yu J et al. Pleural Fluid Amino Acids Contribute to Distinguishing Tuberculosis, Malignant, and Parapneumonic Pleural Effusion Patients. Clin Lab. 2025 Mar 1;71(3).","DOI":"10.7754\/Clin.Lab.2024.240757"},{"issue":"1","key":"4307_CR104","doi-asserted-by":"publisher","first-page":"1790158","DOI":"10.1080\/20013078.2020.1790158","volume":"9","author":"P Luo","year":"2020","unstructured":"Luo P, et al. Metabolic characteristics of large and small extracellular vesicles from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy. J Extracell Vesicles. 2020;9(1):1790158.","journal-title":"J Extracell Vesicles"},{"issue":"2","key":"4307_CR105","first-page":"201","volume":"54","author":"T Xie","year":"2024","unstructured":"Xie T, et al. Differences in (1)HNMR Based Metabolomic Patterns of Malignant and Benign Pleural Effusions. Ann Clin Lab Sci. 2024;54(2):201\u201310.","journal-title":"Ann Clin Lab Sci"},{"key":"4307_CR106","doi-asserted-by":"publisher","first-page":"105201","DOI":"10.1016\/j.jprot.2024.105201","volume":"302","author":"T Dong","year":"2024","unstructured":"Dong T, et al. Quantitative proteomics revealed protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion. J Proteom. 2024;302:105201.","journal-title":"J Proteom"},{"issue":"1","key":"4307_CR107","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/thoraxjnl-2021-217959","volume":"78","author":"S Kassirian","year":"2023","unstructured":"Kassirian S, et al. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis. Thorax. 2023;78(1):32\u201340.","journal-title":"Thorax"},{"issue":"Suppl 3","key":"4307_CR108","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/thorax-2022-219784","volume":"78","author":"ME Roberts","year":"2023","unstructured":"Roberts ME, et al. British Thoracic Society Guideline for pleural disease. Thorax. 2023;78(Suppl 3):s1\u201342.","journal-title":"Thorax"},{"issue":"2","key":"4307_CR109","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10147-016-1073-y","volume":"22","author":"M Feng","year":"2017","unstructured":"Feng M, et al. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis. Int J Clin Oncol. 2017;22(2):283\u201390.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"4307_CR110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000468545","volume":"94","author":"Y Yang","year":"2017","unstructured":"Yang Y, Liu YL, Shi HZ. Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis. Respiration. 2017;94(1):62\u20139.","journal-title":"Respiration"},{"issue":"4","key":"4307_CR111","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.21037\/jtd.2020.02.06","volume":"12","author":"Z Song","year":"2020","unstructured":"Song Z, Cheng G, Zhang Y. PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. J Thorac Dis. 2020;12(4):1385\u201392.","journal-title":"J Thorac Dis"},{"issue":"4","key":"4307_CR112","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/1759-7714.13004","volume":"10","author":"R Shibaki","year":"2019","unstructured":"Shibaki R, et al. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Thorac Cancer. 2019;10(4):815\u201322.","journal-title":"Thorac Cancer"},{"issue":"3","key":"4307_CR113","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jtho.2017.10.034","volume":"13","author":"YH Tseng","year":"2018","unstructured":"Tseng YH, et al. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. J Thorac Oncol. 2018;13(3):447\u201353.","journal-title":"J Thorac Oncol"},{"issue":"03","key":"4307_CR114","first-page":"290","volume":"42","author":"XU Jing","year":"2015","unstructured":"Jing XU, Lin Y, Xiaoqing LIU. Application and Progress of Proteomic Technology on Malignant Pleural Effusion. Cancer Res Prev Treat. 2015;42(03):290\u20134.","journal-title":"Cancer Res Prev Treat"},{"issue":"4","key":"4307_CR115","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1021\/pr049746c","volume":"4","author":"YC Tyan","year":"2005","unstructured":"Tyan YC, et al. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J Proteome Res. 2005;4(4):1274\u201386.","journal-title":"J Proteome Res"},{"issue":"4","key":"4307_CR116","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/pmic.200401041","volume":"5","author":"YC Tyan","year":"2005","unstructured":"Tyan YC, et al. Proteomic analysis of human pleural effusion. Proteomics. 2005;5(4):1062\u201374.","journal-title":"Proteomics"},{"issue":"2","key":"4307_CR117","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12094-013-1054-9","volume":"16","author":"SH Sheng","year":"2014","unstructured":"Sheng SH, Zhu HL. Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy. Clin Transl Oncol. 2014;16(2):153\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"4307_CR118","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","volume":"31","author":"MP Bard","year":"2004","unstructured":"Bard MP, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol. 2004;31(1):114\u201321.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"14","key":"4307_CR119","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/pmic.201200323","volume":"13","author":"JO Park","year":"2013","unstructured":"Park JO, et al. Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics. 2013;13(14):2125\u201334.","journal-title":"Proteomics"},{"key":"4307_CR120","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.lungcan.2019.05.018","volume":"135","author":"S Wang","year":"2019","unstructured":"Wang S, et al. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung. Lung Cancer. 2019;135:116\u201322.","journal-title":"Lung Cancer"},{"issue":"10","key":"4307_CR121","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.amjmed.2022.04.017","volume":"135","author":"S Gayen","year":"2022","unstructured":"Gayen S. Malignant Pleural Effusion: Presentation, Diagnosis, and Management. Am J Med. 2022 Oct;135(10):1188-1192.","journal-title":"Am J Med"},{"issue":"7","key":"4307_CR122","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1515\/cclm-2020-1685","volume":"59","author":"P Pinzani","year":"2021","unstructured":"Pinzani P, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med. 2021;59(7):1181\u2013200.","journal-title":"Clin Chem Lab Med"},{"key":"4307_CR123","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2019.05.034","volume":"134","author":"B Zhang","year":"2019","unstructured":"Zhang B, et al. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. Lung Cancer. 2019;134:108\u201316.","journal-title":"Lung Cancer"},{"key":"4307_CR124","doi-asserted-by":"crossref","unstructured":"Taylor C et al. Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma. Int J Mol Sci. 2020 Nov 29;21(23):9083.","DOI":"10.3390\/ijms21239083"},{"issue":"1","key":"4307_CR125","doi-asserted-by":"publisher","first-page":"91","DOI":"10.21873\/cgp.20170","volume":"17","author":"JW Chang","year":"2020","unstructured":"Chang JW, et al. Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC. Cancer Genomics Proteom. 2020;17(1):91\u2013100.","journal-title":"Cancer Genomics Proteom"},{"key":"4307_CR126","doi-asserted-by":"crossref","unstructured":"Pasini L, Ulivi P. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. J Clin Med. 2019 Jul 9;8(7):998.","DOI":"10.3390\/jcm8070998"},{"key":"4307_CR127","doi-asserted-by":"crossref","unstructured":"Souza VGP et al. Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis. Int J Mol Sci. 2023 May 17;24(10):8894.","DOI":"10.3390\/ijms24108894"},{"issue":"9","key":"4307_CR128","first-page":"653","volume":"24","author":"H Zeng","year":"2021","unstructured":"Zeng H, Tian P, Li W. Progress of Liquid Biopsy in the Diagnosis and Treatment of Lung Cancer with Malignant Pleural Effusion. Zhongguo Fei Ai Za Zhi. 2021;24(9):653\u20139.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"4307_CR129","first-page":"104237","volume":"83","author":"Z Deng","year":"2022","unstructured":"Deng Z, et al. Circulating tumor cell isolation cancer diagnosis prognosis EBioMedicine. 2022;83:104237.","journal-title":"Circulating tumor cell isolation cancer diagnosis prognosis EBioMedicine"},{"issue":"6","key":"4307_CR130","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.7150\/ijms.52306","volume":"18","author":"Y Yu","year":"2021","unstructured":"Yu Y, et al. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing. Int J Med Sci. 2021;18(6):1510\u20138.","journal-title":"Int J Med Sci"},{"issue":"19","key":"4307_CR131","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.7150\/thno.34070","volume":"9","author":"L Tong","year":"2019","unstructured":"Tong L, et al. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019;9(19):5532\u201341.","journal-title":"Theranostics"},{"key":"4307_CR132","doi-asserted-by":"crossref","unstructured":"Hummelink K et al. Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. ERJ Open Res. 2019 Mar 25;5(1):00016-2019.","DOI":"10.1183\/23120541.00016-2019"},{"issue":"2","key":"4307_CR133","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamaoncol.2022.6109","volume":"9","author":"KWC Lee","year":"2023","unstructured":"Lee KWC, et al. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non\u2013Small Cell Lung Cancer. JAMA Oncol. 2023;9(2):261\u20135.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4307_CR134","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229\u201339.","journal-title":"Ann Oncol"},{"key":"4307_CR135","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cca.2013.05.022","volume":"424","author":"S El Messaoudi","year":"2013","unstructured":"El Messaoudi S, et al. Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta. 2013;424:222\u201330.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"4307_CR136","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41598-024-53132-x","volume":"14","author":"B Bixby","year":"2024","unstructured":"Bixby B, et al. Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid. Sci Rep. 2024;14(1):2939.","journal-title":"Sci Rep"},{"key":"4307_CR137","doi-asserted-by":"publisher","first-page":"120273","DOI":"10.1016\/j.cca.2025.120273","volume":"572","author":"M Xie","year":"2025","unstructured":"Xie M, et al. SHOX2 and RASSF1A methylation in diagnosing malignant pleural effusion induced by lung cancer. Clin Chim Acta. 2025;572:120273.","journal-title":"Clin Chim Acta"},{"key":"4307_CR138","doi-asserted-by":"crossref","unstructured":"Markou AN et al. Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer. Cancers (Basel). 2023 Mar 21;15(6):1877.","DOI":"10.3390\/cancers15061877"},{"key":"4307_CR139","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fonc.2019.00931","volume":"9","author":"X Qu","year":"2019","unstructured":"Qu X, et al. Double-Stranded DNA in Exosomes of Malignant Pleural Effusions as a Novel DNA Source for EGFR Mutation Detection in Lung Adenocarcinoma. Front Oncol. 2019;9:931.","journal-title":"Front Oncol"},{"issue":"1","key":"4307_CR140","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-018-0772-6","volume":"17","author":"JY Hur","year":"2018","unstructured":"Hur JY, et al. Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. Mol Cancer. 2018;17(1):15.","journal-title":"Mol Cancer"},{"issue":"1","key":"4307_CR141","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1186\/s12885-018-5138-3","volume":"18","author":"JS Lee","year":"2018","unstructured":"Lee JS, et al. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA. BMC Cancer. 2018;18(1):1236.","journal-title":"BMC Cancer"},{"issue":"2","key":"4307_CR142","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/1759-7714.12932","volume":"10","author":"Y Yao","year":"2019","unstructured":"Yao Y, et al. Detecting EGFR mutations and ALK\/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples. Thorac Cancer. 2019;10(2):193\u2013202.","journal-title":"Thorac Cancer"},{"issue":"1","key":"4307_CR143","doi-asserted-by":"publisher","first-page":"106023","DOI":"10.1016\/j.esmoop.2025.106023","volume":"11","author":"SC Chang","year":"2026","unstructured":"Chang SC, et al. Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective study. ESMO Open. 2026;11(1):106023.","journal-title":"ESMO Open"},{"issue":"6","key":"4307_CR144","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4132\/jptm.2020.08.13","volume":"54","author":"IA Kim","year":"2020","unstructured":"Kim IA, et al. Liquid biopsy using extracellular vesicle\u2013derived DNA in lung adenocarcinoma. J Pathol translational Med. 2020;54(6):453\u201361.","journal-title":"J Pathol translational Med"},{"issue":"3","key":"4307_CR145","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ijc.28054","volume":"133","author":"HS Han","year":"2013","unstructured":"Han HS, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer. 2013;133(3):645\u201352.","journal-title":"Int J Cancer"},{"issue":"2","key":"4307_CR146","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4143\/crt.2014.46.2.178","volume":"46","author":"YM Shin","year":"2014","unstructured":"Shin YM, et al. Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion. Cancer Res Treat. 2014;46(2):178\u201385.","journal-title":"Cancer Res Treat"},{"issue":"4","key":"4307_CR147","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.21037\/tlcr-2024-1205","volume":"14","author":"W Zhao","year":"2025","unstructured":"Zhao W, et al. Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion. Transl Lung Cancer Res. 2025;14(4):1138\u201348.","journal-title":"Transl Lung Cancer Res"},{"key":"4307_CR148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2018.07.018","volume":"124","author":"P Hydbring","year":"2018","unstructured":"Hydbring P, et al. Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression. Lung Cancer. 2018;124:45\u201352.","journal-title":"Lung Cancer"},{"issue":"44","key":"4307_CR149","doi-asserted-by":"publisher","first-page":"e8361","DOI":"10.1097\/MD.0000000000008361","volume":"96","author":"Y Wang","year":"2017","unstructured":"Wang Y, et al. Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesions. Med (Baltim). 2017;96(44):e8361.","journal-title":"Med (Baltim)"},{"key":"4307_CR150","doi-asserted-by":"crossref","unstructured":"Shojaee S et al. Extracellular Vesicle MicroRNA in Malignant Pleural Effusion. Genes (Basel). 2022 Nov 19;13(11):2159.","DOI":"10.3390\/genes13112159"},{"key":"4307_CR151","doi-asserted-by":"crossref","unstructured":"Huang S et al. Circulating miR-1246 Targeting UBE2C, TNNI3, TRAIP, UCHL1 Genes and Key Pathways as a Potential Biomarker for Lung Adenocarcinoma: Integrated Biological Network Analysis. J Pers Med. 2020 Oct 11;10(4):162.","DOI":"10.3390\/jpm10040162"},{"key":"4307_CR152","doi-asserted-by":"publisher","first-page":"666551","DOI":"10.3389\/fonc.2021.666551","volume":"11","author":"A Wang","year":"2021","unstructured":"Wang A, et al. The Long Noncoding RNA LINC00665 Facilitates c-Myc Transcriptional Activity via the miR-195-5p MYCBP Axis to Promote Progression of Lung Adenocarcinoma. Front Oncol. 2021;11:666551.","journal-title":"Front Oncol"},{"key":"4307_CR153","doi-asserted-by":"publisher","first-page":"700168","DOI":"10.3389\/fonc.2021.700168","volume":"11","author":"F Hu","year":"2021","unstructured":"Hu F, et al. Role of Exosomal Non-coding RNAs in Gastric Cancer: Biological Functions and Potential Clinical Applications. Front Oncol. 2021;11:700168.","journal-title":"Front Oncol"},{"issue":"12","key":"4307_CR154","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell. 2022;185(12):2016\u201334.","journal-title":"Cell"},{"key":"4307_CR155","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2147\/OTT.S157551","volume":"11","author":"WW Wang","year":"2018","unstructured":"Wang WW, et al. Combination of long noncoding RNA MALAT1 and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer. Onco Targets Ther. 2018;11:2333\u201344.","journal-title":"Onco Targets Ther"},{"issue":"12","key":"4307_CR156","doi-asserted-by":"publisher","first-page":"e24777","DOI":"10.1002\/jcla.24777","volume":"36","author":"X Huang","year":"2022","unstructured":"Huang X, et al. Construction and analysis of expression profile of exosomal lncRNAs in pleural effusion in lung adenocarcinoma. J Clin Lab Anal. 2022;36(12):e24777.","journal-title":"J Clin Lab Anal"},{"issue":"19","key":"4307_CR157","doi-asserted-by":"publisher","first-page":"23376","DOI":"10.18632\/aging.203632","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p\/ KLF12 axis. Aging. 2021;13(19):23376\u201392.","journal-title":"Aging"},{"issue":"11","key":"4307_CR158","doi-asserted-by":"publisher","first-page":"S501","DOI":"10.1016\/j.jtho.2023.09.936","volume":"18","author":"RSZ Taleb","year":"2023","unstructured":"Taleb RSZ, et al. EP06.06-05 Circular RNA hsa_circ_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion. J Thorac Oncol. 2023;18(11):S501\u20132.","journal-title":"J Thorac Oncol"},{"key":"4307_CR159","unstructured":"Ye Z et al. [Expression of circRNA_051778 in Lung Adenocarcinoma-Associated Malignant and Tuberculous Pleural Effusions and Its Clinical Significance]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55(5):1254\u20131263."},{"key":"4307_CR160","doi-asserted-by":"publisher","first-page":"175346662312086","DOI":"10.1177\/17534666231208632","volume":"17","author":"TT Wei","year":"2023","unstructured":"Wei TT, et al. Development and validation of a machine learning model for differential diagnosis of malignant pleural effusion using routine laboratory data. Ther Adv Respir Dis. 2023;17:17534666231208632.","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"4307_CR161","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/thorax-2022-219608","volume":"78","author":"Y Jung","year":"2023","unstructured":"Jung Y, Kim EY. Artificial intelligence in differentiating malignant from benign pleural effusion: a step beyond conventional methods. Thorax. 2023;78(4):325.","journal-title":"Thorax"},{"issue":"4","key":"4307_CR162","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/thorax-2021-218581","volume":"78","author":"S Wang","year":"2023","unstructured":"Wang S, et al. Differentiation of malignant from benign pleural effusions based on artificial intelligence. Thorax. 2023;78(4):376\u201382.","journal-title":"Thorax"},{"key":"4307_CR163","doi-asserted-by":"publisher","first-page":"1419343","DOI":"10.3389\/fonc.2024.1419343","volume":"14","author":"ZC Xing","year":"2024","unstructured":"Xing ZC, et al. The value of computed tomography-based radiomics for predicting malignant pleural effusions. Front Oncol. 2024;14:1419343.","journal-title":"Front Oncol"},{"issue":"7","key":"4307_CR164","doi-asserted-by":"publisher","first-page":"e18056","DOI":"10.1016\/j.heliyon.2023.e18056","volume":"9","author":"R Han","year":"2023","unstructured":"Han R, et al. Novel clinical radiomic nomogram method for differentiating malignant from non-malignant pleural effusions. Heliyon. 2023;9(7):e18056.","journal-title":"Heliyon"},{"issue":"1","key":"4307_CR165","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12672-023-00835-8","volume":"14","author":"M Wei","year":"2023","unstructured":"Wei M, et al. Development and validation of a radiomics nomogram for diagnosis of malignant pleural effusion. Discov Oncol. 2023;14(1):213.","journal-title":"Discov Oncol"},{"key":"4307_CR166","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.","journal-title":"BMJ"},{"key":"4307_CR167","doi-asserted-by":"publisher","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","volume":"388","author":"KGM Moons","year":"2025","unstructured":"Moons KGM, et al. PROBAST\u2009+\u2009AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025;388:e082505.","journal-title":"BMJ"},{"issue":"10","key":"4307_CR168","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1038\/s41591-025-03953-8","volume":"31","author":"V Sounderajah","year":"2025","unstructured":"Sounderajah V, et al. The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligence. Nat Med. 2025;31(10):3283\u20139.","journal-title":"Nat Med"},{"issue":"19","key":"4307_CR169","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10337-014-2720-y","volume":"77","author":"H Liu","year":"2014","unstructured":"Liu H, et al. Characterization of Volatile Organic Metabolites in Lung Cancer Pleural Effusions by SPME\u2013GC\/MS Combined with an Untargeted Metabolomic Method. Chromatographia. 2014;77(19):1379\u201386.","journal-title":"Chromatographia"},{"key":"4307_CR170","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jchromb.2013.11.038","volume":"945\u2013946","author":"H Liu","year":"2014","unstructured":"Liu H, et al. Investigation of volatile organic metabolites in lung cancer pleural effusions by solid-phase microextraction and gas chromatography\/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;945\u2013946:53\u20139.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4307_CR171","doi-asserted-by":"publisher","first-page":"35110","DOI":"10.1038\/srep35110","volume":"6","author":"YS Ho","year":"2016","unstructured":"Ho YS, et al. Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer. Sci Rep. 2016;6:35110.","journal-title":"Sci Rep"},{"issue":"9","key":"4307_CR172","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1021\/pr5004856","volume":"13","author":"C-W Lam","year":"2014","unstructured":"Lam C-W, Law C-Y. Pleural Effusion Lipoproteins Measured by NMR Spectroscopy for Diagnosis of Exudative Pleural Effusions: A Novel Tool for Pore-Size Estimation. J Proteome Res. 2014;13(9):4104\u201312.","journal-title":"J Proteome Res"},{"issue":"5","key":"4307_CR173","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cncy.21832","volume":"125","author":"L Zennaro","year":"2017","unstructured":"Zennaro L, et al. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers. Cancer Cytopathol. 2017;125(5):341\u20138.","journal-title":"Cancer Cytopathol"},{"issue":"21","key":"4307_CR174","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/1759-7714.14988","volume":"14","author":"D Huang","year":"2023","unstructured":"Huang D, et al. Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma. Thorac Cancer. 2023;14(21):2045\u201356.","journal-title":"Thorac Cancer"},{"key":"4307_CR175","doi-asserted-by":"publisher","first-page":"760683","DOI":"10.3389\/fimmu.2021.760683","volume":"12","author":"X Li","year":"2021","unstructured":"Li X, et al. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion. Front Immunol. 2021;12:760683.","journal-title":"Front Immunol"},{"key":"4307_CR176","doi-asserted-by":"crossref","unstructured":"Cui Y, et al. Intrapleural anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer with malignant pleural effusion: a prospective, single-arm, single-center, phase I trial. Clin Transl Oncol; 2025.","DOI":"10.1007\/s12094-025-04057-y"},{"key":"4307_CR177","doi-asserted-by":"publisher","first-page":"1069555","DOI":"10.3389\/fcell.2022.1069555","volume":"10","author":"Q Duan","year":"2022","unstructured":"Duan Q, et al. Proton-coupled monocarboxylate transporters in cancer: From metabolic crosstalk, immunosuppression and anti-apoptosis to clinical applications. Front Cell Dev Biol. 2022;10:1069555.","journal-title":"Front Cell Dev Biol"},{"key":"4307_CR178","doi-asserted-by":"crossref","unstructured":"Park, H., et al., Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)\u22122 study protocol. Surgical Oncology Insight. 2024;1(2).","DOI":"10.1016\/j.soi.2024.100045"},{"issue":"2","key":"4307_CR179","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol. 2022;17(2):206\u201316.","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"4307_CR180","doi-asserted-by":"publisher","first-page":"108264","DOI":"10.1016\/j.cclet.2023.108264","volume":"34","author":"B Feng","year":"2023","unstructured":"Feng B, et al. Selenium speciation determines the angiogenesis effect through regulating selenoproteins to trigger ROS-mediated cell apoptosis and cell cycle arrest. Chin Chem Lett. 2023;34(11):108264.","journal-title":"Chin Chem Lett"},{"issue":"12","key":"4307_CR181","doi-asserted-by":"publisher","first-page":"2100149","DOI":"10.1002\/adhm.202100149","volume":"10","author":"Z Song","year":"2021","unstructured":"Song Z, et al. Translational Nanotherapeutics Reprograms Immune Microenvironment in Malignant Pleural Effusion of Lung Adenocarcinoma. Adv Healthc Mater. 2021;10(12):2100149.","journal-title":"Adv Healthc Mater"},{"key":"4307_CR182","doi-asserted-by":"publisher","first-page":"1002938","DOI":"10.3389\/fimmu.2022.1002938","volume":"13","author":"X Dong","year":"2022","unstructured":"Dong X, et al. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study. Front Immunol. 2022;13:1002938.","journal-title":"Front Immunol"},{"issue":"11","key":"4307_CR183","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/CM9.0000000000003078","volume":"137","author":"Y Huang","year":"2024","unstructured":"Huang Y, et al. Exosomes in malignant pleural effusions: Sources and applications. Chin Med J (Engl). 2024;137(11):1381\u20133.","journal-title":"Chin Med J (Engl)"},{"issue":"474","key":"4307_CR184","doi-asserted-by":"publisher","first-page":"eaat5690","DOI":"10.1126\/scitranslmed.aat5690","volume":"11","author":"M Guo","year":"2019","unstructured":"Guo M, et al. Autologous tumor cell\u2013derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci Transl Med. 2019;11(474):eaat5690.","journal-title":"Sci Transl Med"},{"issue":"2","key":"4307_CR185","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/cam4.5005","volume":"12","author":"S Zhang","year":"2023","unstructured":"Zhang S, et al. Research progress of tumor-derived extracellular vesicles in the treatment of malignant pleural effusion. Cancer Med. 2023;12(2):983\u201394.","journal-title":"Cancer Med"},{"key":"4307_CR186","doi-asserted-by":"publisher","first-page":"216777","DOI":"10.1016\/j.canlet.2024.216777","volume":"588","author":"Y Fan","year":"2024","unstructured":"Fan Y, et al. Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity. Cancer Lett. 2024;588:216777.","journal-title":"Cancer Lett"},{"issue":"1","key":"4307_CR187","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","volume":"7","author":"Q Ma","year":"2022","unstructured":"Ma Q, et al. A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis. Signal Transduct Target Ther. 2022;7(1):380.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4307_CR188","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"4307_CR189","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1016\/S2352-3026(22)00291-5","volume":"9","author":"Y Hu","year":"2022","unstructured":"Hu Y, et al. CAR T-cell therapies in China: rapid evolution and a bright future. Lancet Haematol. 2022;9(12):e930\u201341.","journal-title":"Lancet Haematol"},{"issue":"30","key":"4307_CR190","doi-asserted-by":"publisher","first-page":"2401264","DOI":"10.1002\/adfm.202401264","volume":"34","author":"S Liu","year":"2024","unstructured":"Liu S, et al. Selenium Nanoparticles Enhance NK Cell-Mediated Tumoricidal Activity in Malignant Pleural Effusion via the TrxR1-IL-18RAP-pSTAT3 Pathway. Adv Funct Mater. 2024;34(30):2401264.","journal-title":"Adv Funct Mater"},{"issue":"6","key":"4307_CR191","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/cts.13260","volume":"15","author":"Y Yang","year":"2022","unstructured":"Yang Y, et al. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta-analysis. Clin Transl Sci. 2022;15(6):1340\u201354.","journal-title":"Clin Transl Sci"},{"key":"4307_CR192","doi-asserted-by":"crossref","unstructured":"Mounsey C et al. Retrospective cohort study of survival length in malignant pleural effusion between 2015 and 2023. BMJ Open Respir Res. 2025 Dec 2;12(1):e003609.","DOI":"10.1136\/bmjresp-2025-003609"},{"issue":"1","key":"4307_CR193","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/1574887114666181204105208","volume":"14","author":"F Meriggi","year":"2019","unstructured":"Meriggi F. Malignant Pleural Effusion: Still a Long Way to Go. Rev Recent Clin Trials. 2019;14(1):24\u201330.","journal-title":"Rev Recent Clin Trials"},{"issue":"12","key":"4307_CR194","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","volume":"69","author":"AO Clive","year":"2014","unstructured":"Clive AO, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098\u2013104.","journal-title":"Thorax"},{"issue":"8","key":"4307_CR195","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.21037\/jtd-2025-113","volume":"17","author":"R Westley","year":"2025","unstructured":"Westley R, De Fonseka D, Bedawi EO. Updates in the management of malignant pleural effusion: a clinical practice review. J Thorac Disease. 2025;17(8):6283\u201395.","journal-title":"J Thorac Disease"},{"key":"4307_CR196","first-page":"p2950751","volume":"2020","author":"L Ferreiro","year":"2020","unstructured":"Ferreiro L, et al. Malignant Pleural Effusion: Diagnosis and Management. Can Respir J. 2020;2020:p2950751.","journal-title":"Can Respir J"},{"issue":"2","key":"4307_CR197","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.chest.2017.08.026","volume":"153","author":"DE Ost","year":"2018","unstructured":"Ost DE, et al. Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions. Chest. 2018;153(2):438\u201352.","journal-title":"Chest"},{"issue":"21","key":"4307_CR198","first-page":"377","volume":"116","author":"B Jany","year":"2019","unstructured":"Jany B, Welte T. Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2019;116(21):377\u201386.","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"4307_CR199","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/ijc.30289","volume":"139","author":"L Li","year":"2016","unstructured":"Li L, et al. Impaired T cell function in malignant pleural effusion is caused by TGF-\u03b2 derived predominantly from macrophages. Int J Cancer. 2016;139(10):2261\u20139.","journal-title":"Int J Cancer"},{"issue":"15","key":"4307_CR200","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.7150\/ijbs.100607","volume":"20","author":"FS Yi","year":"2024","unstructured":"Yi FS, et al. Complement C1q is a key player in tumor-associated macrophage-mediated CD8(+) T cell and NK cell dysfunction in malignant pleural effusion. Int J Biol Sci. 2024;20(15):5979\u201398.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4307_CR201","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ijc.70094","volume":"158","author":"C Zeng","year":"2026","unstructured":"Zeng C, et al. A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion. Int J Cancer. 2026;158(1):172\u201381.","journal-title":"Int J Cancer"},{"issue":"1","key":"4307_CR202","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.chpulm.2025.100227","volume":"4","author":"MJ Wright","year":"2026","unstructured":"Wright MJ, et al. Recurrent Malignant Pleural Effusion Management: Evaluating Quality Gaps, Outcomes, Costs, and Adherence to Guideline-Consistent Care. CHEST Pulmonary. 2026;4(1):100227.","journal-title":"CHEST Pulmonary"},{"key":"4307_CR203","unstructured":"Santotoribio JD. Pleural fluid biomarkers for the diagnosis and management of malignant pleural effusions: a clinical review. Crit Rev Clin Lab Sci. 2025;22:1\u201324."},{"key":"4307_CR204","unstructured":"Zheng WQ et al. Pleural fluid biochemical analyses: a state-of-the-art review. Crit Rev Clin Lab Sci. 2025 Nov 10:1-18."},{"key":"4307_CR205","doi-asserted-by":"publisher","first-page":"175346661878509","DOI":"10.1177\/1753466618785098","volume":"12","author":"CFN Koegelenberg","year":"2018","unstructured":"Koegelenberg CFN, et al. Contemporary best practice in the management of malignant pleural effusion. Ther Adv Respir Dis. 2018;12:1753466618785098.","journal-title":"Ther Adv Respir Dis"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04307-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:03:06Z","timestamp":1781056986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04307-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":205,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4307"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04307-1","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No AI tools were used for literature selection, scientific interpretation, figure generation, or decision-making. All final content was reviewed, revised, and approved by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI use statement"}}],"article-number":"222"}}